Canada’s Drug Agency (CDA-AMC) recommends that Sarclisa be reimbursed by public drug plans for the treatment of patients with newly
Influenza is a major public health concern, causing significant illness, death, economic challenges, and pandemic potential. This underscores the need
Offering additional pre-exposure prophylaxis (PrEP) choices has the potential to increase uptake and effective use of PrEP, and of HIV
Spinal muscular atrophy (SMA) is a rare genetic condition that affects muscle strength and movement in both children and adults.
Post Content
The purpose of this report was to review the available evidence on physician productivity measures. This report was requested by
Canada’s Drug Agency (CDA-AMC) recommends that public drug plans reimburse Rystiggo as an add-on therapy for the treatment of adult
Alternate level of care (ALC) is a designation used and applied by clinical staff to the portion of a patient’s
Registration No: 771800548 Contact Number : +91-8249516996
